Facebook Linkedin RSS Twitter Youtube
Home 2013

Enzyme replacement therapy

Amicus Cuts Jobs, Overhauls GSK Collab, and Acquires Callidus
Drug Discovery

Amicus Cuts Jobs, Overhauls GSK Collab, and Acquires Callidus

BioMarin’s Vimizim Approved for Morquio A Syndrome
Cancer

BioMarin’s Vimizim Approved for Morquio A Syndrome

Takeover Targets: Who Is First on the List?
A-Lists

Takeover Targets: Who Is First on the List?

BioMarin Buys Zacharon for $10M Up Front
Drug Discovery

BioMarin Buys Zacharon for $10M Up Front

GSK Invests $18.6M in Amicus to Expand Fabry Disease Drug Deal
Drug Discovery

GSK Invests $18.6M in Amicus to Expand Fabry Disease Drug Deal

GSK, Angiochem to Work on CNS-Penetrating Drugs for Lysosomal Storage Diseases
Drug Discovery

GSK, Angiochem to Work on CNS-Penetrating Drugs for Lysosomal Storage Diseases

Alexion Pays $610M to Buy Enobia for Hypophosphatasia ERT Candidate
Drug Discovery

Alexion Pays $610M to Buy Enobia for Hypophosphatasia ERT Candidate

Oxyrane Raises $26.5M to Take Lead Enzyme Replacement Therapy Through Phase I/II
Bioprocessing

Oxyrane Raises $26.5M to Take Lead Enzyme Replacement Therapy Through Phase I/II

Enobia Raises $40M to Further Develop Phase II-Stage ERT for Hypophosphatasia
Drug Discovery

Enobia Raises $40M to Further Develop Phase II-Stage ERT for Hypophosphatasia

Oxford BioMedica and ImaginAb Ally to Develop 5T4 Antibody-Based Cancer Imaging Agent
Cancer

Oxford BioMedica and ImaginAb Ally to Develop 5T4 Antibody-Based Cancer Imaging Agent

1234Page 2 of 4
Copyright © 2023 Genetic Engineering & Biotechnology News. All Rights Reserved.